Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 34 Lung Neoplasms 11 Brain Neoplasms 5 Meningeal Carcinomatosis 2 Recurrence 1 Rare Tumor 1 Radiation Pneumonitis 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1 NSCLC 1 Liver Diseases 1 EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1 Digestive System Diseases 1 Carcinoma 1 Aumolertinib 1 Advanced Non-small Cell Lung Cancer 1 Adenocarcinoma 1

Interventions

Cisplatin 55 Carboplatin 50 pembrolizumab 42 Paclitaxel 42 Gemcitabine 28 Pemetrexed 23 Radiotherapy 21 Magnetic Resonance Spectroscopy 20 Radiotherapy, Intensity-Modulated 18 Cetuximab 18 Docetaxel 17 Specimen Handling 16 Nivolumab 16 Fluorouracil 16 Cyclophosphamide 14 durvalumab 13 Bevacizumab 13 Sorafenib 12 Radiation 11 130-nm albumin-bound paclitaxel 11 Sunitinib 10 Platinum 10 1,2-diaminocyclohexaneplatinum II citrate 10 osimertinib 9 Oxaliplatin 8 Irinotecan 8 Ipilimumab 8 Everolimus 8 Drug Therapy 8 Capecitabine 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × aumolertinib × Clear all

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Unknown

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡